0001735276-23-000006.txt : 20230203
0001735276-23-000006.hdr.sgml : 20230203
20230203174542
ACCESSION NUMBER: 0001735276-23-000006
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230201
FILED AS OF DATE: 20230203
DATE AS OF CHANGE: 20230203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tanguler Tolga
CENTRAL INDEX KEY: 0001849458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36407
FILM NUMBER: 23587614
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALNYLAM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001178670
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770602661
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 551-8200
MAIL ADDRESS:
STREET 1: 675 WEST KENDALL STREET
STREET 2: HENRI A. TERMEER SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ALNYLAM PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20020724
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2023-02-01
0
0001178670
ALNYLAM PHARMACEUTICALS, INC.
ALNY
0001849458
Tanguler Tolga
675 WEST KENDALL STREET
HENRI A. TERMEER SQUARE
CAMBRIDGE
MA
02142
0
1
0
0
EVP, Chief Commercial Officer
Common Stock
2023-02-01
4
M
0
5025
0.0
A
5025
D
Common Stock
2023-02-02
4
S
0
73
223.97
D
4952
D
Common Stock
2023-02-02
4
S
0
963
225.8
D
3989
D
Common Stock
2023-02-02
4
S
0
561
226.62
D
3428
D
Common Stock
2023-02-02
4
S
0
4
227.38
D
3424
D
Common Stock
2023-02-03
4
S
0
128
227.68
D
3296
D
Common Stock
2023-02-03
4
S
0
185
230.2
D
3111
D
Common Stock
2023-02-03
4
S
0
865
231.35
D
2246
D
Common Stock
2023-02-03
4
S
0
1293
232.53
D
953
D
Common Stock
2023-02-03
4
S
0
953
233.31
D
0
D
Restricted Stock Units
0.0
2023-02-01
4
M
0
5025
0.0
D
Common Stock
5025
0
D
Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.63 to $228.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.87 to $230.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.90 to $231.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.94 to $232.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.02 to $233.81. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.
On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023).
By: /s/ Cynthia L Anderson, Attorney-in-Fact For: Tolga Tanguler
2023-02-03